Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D47.1Chronic myeloproliferative disease

✓ Billable / specificCC — complication/comorbidity

D47.1 is a valid, billable ICD-10-CM code for chronic myeloproliferative disease. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Looking up by condition? See ICD-10 code for Myelofibrosis, ICD-10 code for Chronic myelosis, ICD-10 code for Myeloproliferative disease, ICD-10 code for Chronic neutrophilic leukemia.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D47.1

D47.1 is the ICD-10-CM diagnosis code for chronic myeloproliferative disease. It belongs to category D47 (other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), block D37-D48 (neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D47 (other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue), D47.1 is specifically for chronic myeloproliferative disease. Related codes cover mast cell neoplasms of uncertain behavior (D47.0), monoclonal gammopathy (D47.2), essential (hemorrhagic) thrombocythemia (D47.3), Osteomyelofibrosis (D47.4), neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (D47.9) and other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue (D47.Z).

Don't report D47.1 together with the conditions in its Excludes1 note: atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-), chronic myeloid leukemia BCR/ABL-positive (C92.1-), myelofibrosis NOS (D75.81), myelophthisic anemia (D61.82) and 2 more.

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 238.76 (myelofibrosis with myeloid metaplasia) and 238.79 (other lymphatic and hematopoietic tissues).

Coding notes

Applicable toConditions and synonyms classified to this code
  • Chronic neutrophilic leukemia
  • Myeloproliferative disease, unspecified
Excludes1Not coded here — never report together with this code
  • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
  • chronic myeloid leukemia BCR/ABL-positive (C92.1-)
  • myelofibrosis NOS (D75.81)
  • myelophthisic anemia (D61.82)
  • myelophthisis (D61.82)
  • secondary myelofibrosis NOS (D75.81)

Notes that apply from higher levels

Instructions written at a parent level also apply to D47.1.

Broader instructions also apply from D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes and Chapter 2: Neoplasms.

Alphabetic index entries

6 entries

Terms in the official ICD-10-CM index that lead to D47.1.

Codes whose notes reference D47.1

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 238.76Myelofibrosis with myeloid metaplasiaapproximate
  • 238.79Other lymphatic and hematopoietic tissuesapproximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about D47.1

Is D47.1 billable?

Yes. D47.1 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D47.1 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D47.1 as a principal diagnosis.

Is D47.1 a CC or MCC?

D47.1 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does D47.1 group to?

D47.1 is used in the MS-DRG v44.0 logic for MS-DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC), MS-DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC), MS-DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC), MS-DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC), MS-DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC), MS-DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC) and 3 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for D47.1?

The CMS General Equivalence Mappings map D47.1 to ICD-9-CM 238.76 and 238.79.